Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

Rechercher

Affichage: 9 résultats.
    • Article de périodique
    Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer : the RadiOxCape study
    Machiels, Jean-Pascal[UCL] Duck, Lionel[UCL] Honhon, Brigitte Coster, Bernard Coche, Jean-Charles Scalliet, Pierre[UCL] Humblet, Yves[UCL] Aydin, Selda[UCL] Kerger, Jean-François[UCL] Remouchamps, Vincent Canon, Jean-Luc Van Maele, Philippe Gilbeau, Laurent Laurent, Stéphanie[UCL] Kirkove, Carine[UCL] Octave-Prignot, Michelle[UCL] Baurain, Jean-François[UCL] Kartheuser, Alex[UCL] Sempoux, Christine[UCL] (2005) Annals of Oncology: official journal of the European Society for Medical Oncology / ESMO — Vol. 16, no. 12, p. 1898-1905 (2005)
    • Communication
    A phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients (Pts) with metastatic colorectal cancer (CRC) to investigate the interaction between the agents.
    Teipar, S Humblet, Yves[UCL] Lin, E Bono, P Jalava, T Kay, A Masson, E Laurent, D Joensuu, H Van Cutsem, E. (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)
    • Communication
    An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).
    Humblet, Yves[UCL] Peeters, Marie-Rose[UCL] Bleiberg, H. Stupp, R. Sessa, C. Roth, A Nippgen, J Nolting, A Stuart, P Giaccone, Giuseppe (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)
    • Communication
    Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study
    Cervantes, A. Humblet, Yves[UCL] Casac, E. Van Cutsem, Emmanuel[UCL] Sastre, J. André, Thibaut[UCL] Van Laethem, J. Zubel, A. Gascon, N. de Gramont, A. (2005) —
    • Article de périodique
    Progress in the treatment of advanced CRC
    Humblet, Yves[UCL] (2005) Hospital Pharmacy Europe — Vol. 23, p. 26-28 (2005)
    • Communication
    Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.
    Rubio, ED Humblet, Yves[UCL] Tabernero, J. Van Cutsem, E. Cervantes, A. André, Thibaut[UCL] Soulie, P Corretge, S Kisker, O. de Gramont, A. (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)
    • Communication
    A multicenter Phase II trial of gefitinib 500 mg/day in 192 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy.
    Vergote, Ignace[UCL] Humblet, Yves[UCL] Van Cutsem, Emmanuel[UCL] Van Belle, S. Kerger, Joseph Van Laethem, J. Canon, J. Forget, F. Amant, Frederic[UCL] Van Oosterom, A. (2005) —
    • Communication
    Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963.
    Levi, F Humblet, Yves[UCL] Gorlia, Thierry[UCL] Tubiana, N Smaaland, R Canon, JL. Lentz, MA. Focan, C. Bjarnason, G Giacchetti, S (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)
    • Communication
    A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data
    Vergote, IB Humblet, Yves Van Cutsem, E. Van Belle, S. Kerger, Joseph Van Laethem, JL Canon, JL. Forget, F. Strobbe, E Van Oosterom, A. (2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Orlando (Fl)